>
Switch to:

Biomarin Pharmaceutical Gross Profit

: $1,372 Mil (TTM As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Biomarin Pharmaceutical's gross profit for the three months ended in Sep. 2021 was $305 Mil. Biomarin Pharmaceutical's gross profit for the trailing twelve months (TTM) ended in Sep. 2021 was $1,372 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Biomarin Pharmaceutical's gross profit for the three months ended in Sep. 2021 was $305 Mil. Biomarin Pharmaceutical's Revenue for the three months ended in Sep. 2021 was $409 Mil. Therefore, Biomarin Pharmaceutical's Gross Margin % for the quarter that ended in Sep. 2021 was 74.67%.

Biomarin Pharmaceutical had a gross margin of 74.67% for the quarter that ended in Sep. 2021 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Biomarin Pharmaceutical was 83.88%. The lowest was 71.82%. And the median was 81.41%.

Warning Sign:

Biomarin Pharmaceutical Inc gross margin has been in long term decline. The average rate of decline per year is -2.4%.


Biomarin Pharmaceutical Gross Profit Historical Data

The historical data trend for Biomarin Pharmaceutical's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Profit
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 907.23 1,071.86 1,175.99 1,344.58 1,336.19

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.99 325.99 365.90 374.63 305.21

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Gross Profit Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Gross Profit distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Gross Profit falls into.



Biomarin Pharmaceutical Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Biomarin Pharmaceutical's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as

Gross Profit (A: Dec. 2020 )=Revenue - Cost of Goods Sold
=1860.461 - 524.272
=1,336

Biomarin Pharmaceutical's Gross Profit for the quarter that ended in Sep. 2021 is calculated as

Gross Profit (Q: Sep. 2021 )=Revenue - Cost of Goods Sold
=408.742 - 103.537
=305

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,372 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Biomarin Pharmaceutical's Gross Margin % for the quarter that ended in Sep. 2021 is calculated as

Gross Margin % (Q: Sep. 2021 )=Gross Profit (Q: Sep. 2021 ) / Revenue (Q: Sep. 2021 )
=(Revenue - Cost of Goods Sold) / Revenue
=305 / 408.742
=74.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Biomarin Pharmaceutical  (NAS:BMRN) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Biomarin Pharmaceutical had a gross margin of 74.67% for the quarter that ended in Sep. 2021 => Durable competitive advantage


Biomarin Pharmaceutical Gross Profit Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)